Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 1,743 trials

Epithelial Ovarian Cancer: Sentinel Node Detection Study

We are testing two tracers to see if they improve the detection of sentinel lymph nodes in patients with early-stage epithelial ovarian cancer. This may help in better understanding the cancer's spread and improving surgical outcomes.

Ovarian Epithelial Cancer>2 yearsEfficacy phase (II)Standard MedicinesGynecology and ObstetricsOncology

Hypophosphatasia: ALXN1850 Treatment Study

We are studying a new treatment called ALXN1850 for adolescents and adults with hypophosphatasia who haven't been treated before. The goal is to see if it improves their daily functioning and quality of life compared to a placebo.

Hypophosphatasia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyHematology

Axial Spondyloarthritis: Imaging with Technetium-labeled Certolizumab Pegol

We are studying whether a new imaging method can improve treatment decisions for people with axial spondyloarthritis. This may help doctors better assess disease activity and predict treatment responses.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Fosigotifator for Vanishing White Matter Disease

We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.

Vanishing White Matter Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

HER2-Positive Biliary Tract Cancer: GemCis with Trastuzumab and Pembrolizumab

We are studying a combination of treatments for people with HER2-positive biliary tract cancer to see if it improves response rates and overall survival. This trial aims to assess both the effectiveness and safety of the treatment.

Cholangiocarcinoma and Gallbladder Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Head Trauma: Safety of Inhaled Isoflurane

We are evaluating the safety of using inhaled Isoflurane for sedation in patients with head trauma. This study aims to ensure that this method is safe for these patients.

Head Trauma>2 yearsEfficacy phase (II)Internal MedicineNeurologyOtolaryngology

Lung Cancer Treatment: Livmoniplimab and Budigalimab

We are studying a new combination of drugs for adults with untreated metastatic non-squamous non-small cell lung cancer. The goal is to see if this combination works better than a standard treatment with pembrolizumab and chemotherapy.

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Mild Age-Related Hearing Loss: DX243 Treatment

We are testing a new treatment for people with mild age-related hearing loss to see if it is safe and effective. The study starts with healthy volunteers before moving to patients.

Age-Related Hearing Loss>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineOtolaryngology

B-cell Non-Hodgkin Lymphoma: Surovatamig Treatment Study

We are studying how well surovatamig works and its safety for adults with certain types of blood cancers. This trial aims to learn more about its effects on lymphoma and patient experiences.

Relapsed or Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Cardiovascular Disease: New Care Strategies for Type 1 Diabetes

We are testing a new care approach to reduce cardiovascular disease risk in people with type 1 diabetes. This study also evaluates the safety of a medication called finerenone in this high-risk group.

Type 1 Diabetes>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Acute Myeloid Leukemia: MB-dNPM-1-TCR.1 Treatment

We are studying a new therapy for patients with relapsed or refractory acute myeloid leukemia. The goal is to understand its safety and how well it works compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Lupus Nephritis: Obinutuzumab for Adolescents

We are studying the effects of obinutuzumab in adolescents with active lupus nephritis to see if it is more effective than a placebo. The trial also includes younger children to evaluate safety and how the drug works in them.

Lupus Nephritis>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteNephrologyPediatricsRheumatology

Acute Myeloid Leukemia: Emavusertib Treatment Study

We are testing a new drug, Emavusertib, for patients with acute myeloid leukemia who still have traces of the disease while on other treatments. The goal is to see if it improves their condition.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Oncology

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology

Klinefelter Syndrome: Testosterone Treatment in Puberty

We are studying how testosterone replacement therapy affects boys with Klinefelter syndrome during puberty. This includes looking at changes in body composition, growth, and overall development.

Klinefelter Syndrome>2 yearsMonitoring phase (IV)Standard MedicinesEndocrinologyUrology

Advanced Solid Tumors: PF-08046050 Study

We are investigating a new treatment for adults with advanced solid tumors. This study aims to understand how well it works compared to current options.

Small Cell Lung CancerPancreatic CarcinomaColorectal Cancer>2 yearsSafety phase (I)Oncology

Colchicine for Heart and Kidney Health in Chronic Kidney Disease

We are studying whether low-dose colchicine can help prevent heart problems and slow kidney disease in people with moderate chronic kidney disease. This trial will also look at the safety of the treatment and its effects on inflammation.

Chronic Kidney Disease>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyNephrology

Advanced Neuroendocrine Cancers: DAREON™-7 Study

We are testing how well different doses of BI 764532 work with chemotherapy for people with advanced neuroendocrine cancers. The goal is to see which doses are best tolerated by patients.

Neuroendocrine CarcinomaExtra-pulmonary Neuroendocrine CarcinomaPulmonary Large Cell Neuroendocrine Carcinoma>2 yearsSafety phase (I)Oncology

Pancreatic Cancer: FOLFIRINOX3 Treatment

We are testing a chemotherapy combination for patients with advanced pancreatic cancer who cannot undergo surgery. The goal is to see if it is safe and effective as a first treatment option.

Advanced Pancreatic Cancer>2 yearsEfficacy phase (II)Oncology

Acute Myeloid Leukemia: Personalized Treatment Based on FLT3 Mutation

We are studying a new treatment strategy for patients with FLT3-positive AML, using a biomarker to tailor therapy. The goal is to see if this approach improves survival compared to standard treatments.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology